China’s COVID-19 vaccine, CoronaVac, has general efficacy of less than 60% in Brazil trials

According to two sources who have seen the lab results, China’s CoronaVac, its COVID-19 vaccine, developed by Sinovac Biotech, has a general efficacy of less than 60% in clinical trial in Brazil.

Brazil’s Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans on releasing the general efficacy of the test results of China’s CoronaVac, as it seeks emergency use for the shot from health regulator Anvisa.



Categories: Creativity, Entrepreneurship, HR & Organization, Strategy, Sustainability

Tags: , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: